Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 127Colonic Neoplasms 71Rectal Neoplasms 56Neoplasm Metastasis 22Pancreatic Neoplasms 21Stomach Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia 11Carcinoma, Hepatocellular 11Neoplasms 10Lymphoma 10Burkitt Lymphoma 8Adenocarcinoma Of Esophagus 8Cholangiocarcinoma 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Esophageal Neoplasms 5Leukemia, Biphenotypic, Acute 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Digestive System Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Gallbladder Neoplasms 3Biliary Tract Neoplasms 3Rectal Diseases 2Neurotoxicity Syndromes 2

Interventions

Oxaliplatin 4Sodium Chloride 3Paclitaxel 3Carboplatin 3xaliproden 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Magnesium Sulfate 2Leucovorin 2Fluorouracil 2Calcium Gluconate 2neurotropin 1glutamic acid diethyl ester 1Vitamin E 1Thioctic Acid 1Temozolomide 1Saline Solution 1Radiosurgery 1Prednisolone 1Methylprednisolone 1Memantine 1Lamotrigine 1Ketamine 1Glutathione 1Glutamic Acid 1Ginkgo Extract 1Gabapentin 1Duloxetine Hydrochloride 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neurotoxicity Syndromes × Leucovorin × Clear all
NCT01279681 2017-12-08

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
32 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡